Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Simple item page
buir.contributor.authorÖzçelik, Tayfun
dc.citation.epageeabd4585-12en_US
dc.citation.issueNumber6515en_US
dc.citation.spageeabd4585-1en_US
dc.citation.volumeNumber370en_US
dc.contributor.authorBastard, P.
dc.contributor.authorRosen, L. B.
dc.contributor.authorZhang, Q.
dc.contributor.authorMichailidis, E.
dc.contributor.authorHoffmann, H.-H.
dc.contributor.authorZhang, Y.
dc.contributor.authorDorgham, K.
dc.contributor.authorPhilippot, Q.
dc.contributor.authorRosain, J.
dc.contributor.authorBéziat, V.
dc.contributor.authorManry, J.
dc.contributor.authorShaw, E.
dc.contributor.authorHaljasmägi, L.
dc.contributor.authorPeterson, P.
dc.contributor.authorLorenzo, L.
dc.contributor.authorBizien, L.
dc.contributor.authorTrouillet-Assant, S.
dc.contributor.authorDobbs, K.
dc.contributor.authorAlmeida de Jesus, A.
dc.contributor.authorBelot, A.
dc.contributor.authorKallaste, A.
dc.contributor.authorCatherinot, E.
dc.contributor.authorTandjaoui-Lambiotte, Y.
dc.contributor.authorLe Pen, J.
dc.contributor.authorKerner, G.
dc.contributor.authorBigio, B.
dc.contributor.authorSeeleuthner, Y.
dc.contributor.authorYang, R.
dc.contributor.authorBolze, A.
dc.contributor.authorSpaan, A. N.
dc.contributor.authorDelmonte, O. M.
dc.contributor.authorAbers, M. S.
dc.contributor.authorAiuti, A.
dc.contributor.authorCasari, G.
dc.contributor.authorLampasona, V.
dc.contributor.authorPiemonti, L.
dc.contributor.authorCiceri, F.
dc.contributor.authorBilguvar, K.
dc.contributor.authorLifton, R. P.
dc.contributor.authorVasse, M.
dc.contributor.authorSmadja, D. M.
dc.contributor.authorMigaud, M.
dc.contributor.authorHadjadj, J.
dc.contributor.authorTerrier, B.
dc.contributor.authorDuffy, D.
dc.contributor.authorQuintana-Murci, L.
dc.contributor.authorvan de Beek, D.
dc.contributor.authorRoussel, L.
dc.contributor.authorVinh, D. C.
dc.contributor.authorTangye, S. G.
dc.contributor.authorHaerynck, F.
dc.contributor.authorDalmau, D.
dc.contributor.authorMartinez-Picado, J.
dc.contributor.authorBrodin, P.
dc.contributor.authorNussenzweig, M. C.
dc.contributor.authorBoisson-Dupuis, S.
dc.contributor.authorRodríguez-Gallego, C.
dc.contributor.authorVogt, G.
dc.contributor.authorMogensen, T. H.
dc.contributor.authorOler, A. J.
dc.contributor.authorGu, J.
dc.contributor.authorBurbelo, P. D.
dc.contributor.authorCohen, J. I.
dc.contributor.authorBiondi, A.
dc.contributor.authorBettini, L. R.
dc.contributor.authorD'Angio, M.
dc.contributor.authorBonfanti, P.
dc.contributor.authorRossignol, P.
dc.contributor.authorMayaux, J.
dc.contributor.authorRieux-Laucat, F.
dc.contributor.authorHusebye, E. S.
dc.contributor.authorFusco, F.
dc.contributor.authorUrsini, M. V.
dc.contributor.authorImberti, L.
dc.contributor.authorSottini, A.
dc.contributor.authorPaghera, S.
dc.contributor.authorQuiros-Roldan, E.
dc.contributor.authorRossi, C.
dc.contributor.authorCastagnoli, R.
dc.contributor.authorMontagna, D.
dc.contributor.authorÖzçelik, Tayfun
dc.contributor.authorLicari, A.
dc.contributor.authorMarseglia, G. L.
dc.contributor.authorDuval, X.
dc.contributor.authorGhosn, J.
dc.contributor.authorTsang, J. S.
dc.contributor.authorGoldbach-Mansky, R.
dc.contributor.authorKisand, K.
dc.contributor.authorLionakis, M. S.
dc.contributor.authorPuel, A.
dc.contributor.authorZhang, S.- Y.
dc.contributor.authorHolland, S. M.
dc.contributor.authorGorochov, G.
dc.contributor.authorJouanguy, E.
dc.contributor.authorRice, C. M.
dc.contributor.authorCobat, A.
dc.contributor.authorNotarangelo, L. D.
dc.contributor.authorAbel, L.
dc.contributor.authorSu, H. C.
dc.contributor.authorCasanova, J. L.
dc.contributor.authorHGID Lab
dc.contributor.authorNIAID-USUHS Immune Response to COVID Group
dc.contributor.authorCOVID Clinicians
dc.contributor.authorCOVID-STORM Clinicians
dc.contributor.authorImagine COVID Group
dc.contributor.authorFrench COVID Cohort Study Group
dc.contributor.authorMilieu Intérieur Consortium
dc.contributor.authorCoV-Contact Cohort
dc.contributor.authorAmsterdam UMC Covid-19 Biobank
dc.contributor.authorCOVID Human Genetic Effort
dc.date.accessioned2021-03-31T11:49:38Z
dc.date.available2021-03-31T11:49:38Z
dc.date.issued2020
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractInterindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.en_US
dc.description.provenanceSubmitted by Evrim Ergin (eergin@bilkent.edu.tr) on 2021-03-31T11:49:38Z No. of bitstreams: 1 Autoantibodies_against_type_I_IFNs_in_patients_with_life-threatening_COVID-19.pdf: 2817270 bytes, checksum: 9fe77c1f8e6b3fe06eda2ef60ad128e6 (MD5)en
dc.description.provenanceMade available in DSpace on 2021-03-31T11:49:38Z (GMT). No. of bitstreams: 1 Autoantibodies_against_type_I_IFNs_in_patients_with_life-threatening_COVID-19.pdf: 2817270 bytes, checksum: 9fe77c1f8e6b3fe06eda2ef60ad128e6 (MD5) Previous issue date: 2020en
dc.identifier.doi10.1126/science.abd4585en_US
dc.identifier.issn1095-9203
dc.identifier.urihttp://hdl.handle.net/11693/76058
dc.language.isoEnglishen_US
dc.relation.isversionofhttps://doi.org/10.1126/science.abd4585en_US
dc.source.titleScienceen_US
dc.titleAutoantibodies against type I IFNs in patients with life-threatening COVID-19en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Autoantibodies_against_type_I_IFNs_in_patients_with_life-threatening_COVID-19.pdf
Size:
2.69 MB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.69 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Scholarly Publications - Molecular Biology and Genetics